Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 64
2021 88
2022 101
2023 81
2024 57
2025 34

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

371 results

Results by year

Filters applied: . Clear all
Page 1
A Second Opportunity for the Peptide-Based Analogues with γ-Lactam at the P1 Position: Human Cathepsin S Inhibition.
Previti S, Iraci N, Calcaterra E, Ettari R, Zappalà M. Previti S, et al. Pharmaceuticals (Basel). 2025 Sep 28;18(10):1462. doi: 10.3390/ph18101462. Pharmaceuticals (Basel). 2025. PMID: 41155577 Free PMC article.
Background/Objectives: SARS-CoV-2 pandemic led to the identification of peptide-based main protease (M(pro)) inhibitors. ...During the selectivity assessment of an in-house Michael acceptors targeting SARS-CoV-2 M(pro), we unexpectedly ob …
Background/Objectives: SARS-CoV-2 pandemic led to the identification of peptide-based main protease (M(pro)) inhibitors …
Clinical Benefits of Exogenous Ketosis in Adults with Disease: A Systematic Review.
Mohib O, Bomans S, Jimenez Garcia B, Leemans L, Ligneel C, De Waele E, Beckwée D, Janssens P. Mohib O, et al. Nutrients. 2025 Sep 30;17(19):3125. doi: 10.3390/nu17193125. Nutrients. 2025. PMID: 41097203 Free PMC article. Review.
BACKGROUND/OBJECTIVES: Ketone bodies are increasingly studied for their potential therapeutic effects, particularly through exogenous ketosis, in a variety of diseases. ...Exogenous ketosis demonstrated potential benefits across multiple conditions, including Alzheimer's d …
BACKGROUND/OBJECTIVES: Ketone bodies are increasingly studied for their potential therapeutic effects, particularly through exogenous …
SARS-CoV-2 Main Protease Inhibitors Containing 5-Substituted Benzothiazole-2-carbonyl Moieties at the P1' Site and Their Derivatives.
Tsuji K, Kobayakawa T, Higashi-Kuwata N, Ishii T, Shinohara K, Yamamoto R, Miura Y, Wada N, Mitsuya H, Tamamura H. Tsuji K, et al. ACS Omega. 2025 Aug 27;10(36):41608-41619. doi: 10.1021/acsomega.5c05168. eCollection 2025 Sep 16. ACS Omega. 2025. PMID: 40978346 Free PMC article.
Development of anti-SARS-CoV-2 agents is still required because of the appearance of drug-resistant strains, and targeting the main protease (M(pro)) of SARS-CoV-2 is a powerful way to develop therapeutics against COVID-19. …
Development of anti-SARS-CoV-2 agents is still required because of the appearance of drug-resistant strains, and target …
U.S. states opting out of expanded methadone take-home policies and associated mortality.
Roy V, Buonora MJ, Murray-Krezan C, Fabio A, Joudrey PJ. Roy V, et al. J Subst Use Addict Treat. 2025 Dec;179:209800. doi: 10.1016/j.josat.2025.209800. Epub 2025 Sep 6. J Subst Use Addict Treat. 2025. PMID: 40921251
BACKGROUND: Historically, federal regulations limited take-home methadone doses largely due to concerns about methadone-related overdose. In response to the COVID-19 pandemic, an emergency federal policy in March 2020 permitted states to expand take-home methadone d …
BACKGROUND: Historically, federal regulations limited take-home methadone doses largely due to concerns about methadone-related overdose. In …
Discovery and mechanistic insights of dibenzoylmethane as a broad spectrum inhibitor of coronavirus.
Sun Y, Shu X, Chen L, Shang W, Zhang Y, Xiao G, Zhang L. Sun Y, et al. PLoS Pathog. 2025 Sep 8;21(9):e1013492. doi: 10.1371/journal.ppat.1013492. eCollection 2025 Sep. PLoS Pathog. 2025. PMID: 40920846 Free PMC article.
Despite significant advances in vaccine and antiviral development, the high mutability of human coronaviruses (HCoVs), such as SARS-CoV-2, presents a major challenge in treating these infections. Effective, broad-spectrum antiviral drugs are urgently needed t …
Despite significant advances in vaccine and antiviral development, the high mutability of human coronaviruses (HCoVs), such as SARS- …
Digitally enhanced ketogenic diet versus low-fat diet for cardio-renal-metabolic health in a predominantly Hispanic adult population with overweight or obesity: Pilot randomised clinical trial.
Du Y, Wang J, Li S, Meireles C, Saliba A, Castillo A, Goros M, Gelfond J, Choi BY, Qi L, Li C, Sharma K. Du Y, et al. Diabetes Obes Metab. 2025 Nov;27(11):6154-6166. doi: 10.1111/dom.70000. Epub 2025 Aug 6. Diabetes Obes Metab. 2025. PMID: 40770907 Free PMC article. Clinical Trial.
RESULTS: The study successfully enrolled the planned sample size (N = 60) within 1 year despite COVID-19-related challenges. Retention rates were 73.3% at 3 months and 71.7% at 6 months. ...No significant differences in clinical or metabolic outcomes were observed b …
RESULTS: The study successfully enrolled the planned sample size (N = 60) within 1 year despite COVID-19-related challenges. R …
Reducing stigma and expanding methadone access in the U.S.: the Modernizing Opioid Treatment Access Act and beyond.
Nunes JC, Adinoff B. Nunes JC, et al. Am J Drug Alcohol Abuse. 2025;51(4):413-418. doi: 10.1080/00952990.2025.2525405. Epub 2025 Jul 28. Am J Drug Alcohol Abuse. 2025. PMID: 40720387
While opioid treatment programs have played a critical role in methadone delivery, their restrictive model can increase stigma and limit access, particularly in underserved areas. The COVID-19 pandemic demonstrated that 30-day take-home methadone-dispensed through o …
While opioid treatment programs have played a critical role in methadone delivery, their restrictive model can increase stigma and limit acc …
Treatment initiations and opioid overdoses among recently incarcerated people after adoption of the take-home methadone policy.
Barsky BA, Yan S, Rosenthal MB. Barsky BA, et al. Drug Alcohol Depend. 2025 Sep 1;274:112775. doi: 10.1016/j.drugalcdep.2025.112775. Epub 2025 Jul 3. Drug Alcohol Depend. 2025. PMID: 40675010 Free article.
Take-home methadone flexibilities adopted at the COVID-19 pandemic's outset may have facilitated opioid use disorder treatment initiations and prevented opioid overdoses for this population. ...
Take-home methadone flexibilities adopted at the COVID-19 pandemic's outset may have facilitated opioid use disorder treatment …
Unveiling novel pharmacophores and hit compounds for the development of anti-virals to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Dávila B, Fló M, Ruatta S, Lorenzelli F, Medeiros A, Bastidas J, Rodríguez G, Aguilera E, García MF, Romero AH, Park S, Heo J, Lee H, Jeon Y, Park KP, Shum D, López V, Couto M, Cerecetto H, Comini MA. Dávila B, et al. Bioorg Chem. 2025 Aug;163:108724. doi: 10.1016/j.bioorg.2025.108724. Epub 2025 Jul 4. Bioorg Chem. 2025. PMID: 40639033
The respiratory infection COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which continues to spread worldwide causing more than a million deaths yearly. ...Additionally, 3 out of 26 tested compounds (11 %) …
The respiratory infection COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV- …
Risk of drug-related mortality among people receiving opioid-agonist treatment during the COVID-19 pandemic in Scotland.
Glancy M, McAuley A, Palmateer N, Trayner K, Yeung A, Barnsdale L, Priyadarshi S, Horsburgh K, Hickman M, Hutchinson S. Glancy M, et al. Int J Drug Policy. 2025 Sep;143:104912. doi: 10.1016/j.drugpo.2025.104912. Epub 2025 Jul 6. Int J Drug Policy. 2025. PMID: 40618656 Free article.
BACKGROUND: The COVID-19 pandemic led to changes in delivery of opioid-agonist treatment (OAT) and risk of drug-related harm in Scotland. ...RESULTS: Between 2011 and 2022, 49,000 individuals accessed OAT, contributing 366,344 person years of follow-up, during which …
BACKGROUND: The COVID-19 pandemic led to changes in delivery of opioid-agonist treatment (OAT) and risk of drug-related harm i …
371 results